Erste Asset Management GmbH Acquires 498,898 Shares of Pfizer Inc. $PFE

Erste Asset Management GmbH lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 302.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 663,819 shares of the biopharmaceutical company’s stock after purchasing an additional 498,898 shares during the period. Erste Asset Management GmbH’s holdings in Pfizer were worth $16,595,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. United Bank boosted its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares during the period. Sei Investments Co. boosted its position in Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after buying an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC boosted its position in Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after buying an additional 31,896 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Citigroup raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, Guggenheim raised their target price on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer Price Performance

PFE opened at $25.66 on Tuesday. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a market cap of $146.22 billion, a price-to-earnings ratio of 19.58 and a beta of 0.34. The stock has a fifty day simple moving average of $26.59 and a two-hundred day simple moving average of $26.30. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported encouraging Phase 2b data for its once-monthly obesity drug, showing about 15.9% to 16% weight loss, reinforcing hopes that the company could become a more meaningful player in the fast-growing weight-loss market. Pfizer’s obesity drug shows 16% weight loss in phase 2b study
• Positive Sentiment: The U.S. FDA expanded approval of Pfizer’s HYMPAVZI for additional hemophilia A and B patient groups, including pediatric patients, which should widen the drug’s addressable market and support future sales growth. U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
• Positive Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside in PFE, reflecting rising near-term optimism around the company’s pipeline news.
• Neutral Sentiment: Pfizer also presented at Goldman Sachs’ Global Healthcare Conference, but no major new strategic update was highlighted in the available summary. Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Competition in obesity drugs remains intense, with another company reporting strong weight-loss results, reminding investors that Pfizer will need to keep delivering to compete in this high-profile market. Sciwind Reports 12.8% Weight Loss As Global Expansion Talks Deepen

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.